Table 4.
B-Cell Populations in the Bone Marrow and Spleen of 2-Month–Old Notch2HCS Mutant Male Mice and Sex-Matched Littermate Controls Treated with Anti-Notch2 NRR or Anti-Ragweed Control Antibody, Both at 10 mg/kg, for 4 Weeks
| Gate used |
B220+IgM− |
B220+CD19+CD117− |
B220−CD19− |
|||
|---|---|---|---|---|---|---|
| Cell population | CD19−CD117− Pre-pro-B |
CD19+CD117+ Pro-B |
CD19+CD117− Pre-B |
IgM+ | IgMhigh | CD138+ plasma |
| Bone marrow | ||||||
| Control | ||||||
| Control | 48.1 (33.8–62.4) | 3.5 (1.2–5.7) | 39.3 (23.8–54.8) | 45.2 (38.3–52.1) | 29.2 (25.3–33.2) | 5.2 (4.0–6.5) |
| Notch2HCS | 54.4 (51.6–57.3) | 2.7 (2.2–3.1) | 34.5 (28.7–40.2) | 55.7 (46.8–64.5) | 21.8 (9.4–34.2) | 4.5 (3.4–5.6) |
| Anti-Notch2 NRR | ||||||
| Control | 53.9 (41.3–66.4) | 2.5 (1.8–3.2) | 35.2 (25.5–45.1) | 48.6 (34.5–62.8) | 22.8 (7.5–38.1) | 6.3 (5.4–7.2) |
| Notch2HCS | 56.6 (44.2–69.1) | 2.2 (0.7–3.7) | 33.0 (16.7–49.7) | 49.7 (42.0–57.4) | 21.6 (10.1–33.1) | 5.1 (3.1–6.8) |
| Spleen | ||||||
| Control | NA | NA | NA | |||
| Control | 52.4 (50.7–54.1) | 16.6 (14.0–19.2) | 0.9 (0.7–1.1) | |||
| Notch2HCS | 52.8 (48.8–56.3) | 31.2 (23.1–39.3)∗ | 0.9 (0.2–1.6) | |||
| Anti-Notch2 NRR | ||||||
| Control | 49.3 (42.3–56.3) | 9.9 (7.1–12.7)† | 0.8 (0.5–1.0) | |||
| Notch2HCS | 50.1 (46.7–53.4) | 9.6 (5.9–13.4)‡ | 0.9 (0.7–1.1) | |||
Data are expressed as mean (95% CI) percentages within the indicated gates of four biological replicates.
NA, not applicable; NRR, negative regulatory region.
∗
P < 0.05 Notch2HCS versus control.
†
P < 0.05 anti-ragweed antibody–treated versus anti-Notch2 NRR antibody–treated wild-type mice.
‡
P < 0.05 anti-ragweed–treated versus anti-Notch2 NRR antibody–treated Notch2HCS mice.